Risk Factors for Infection, Predictors of Severe Disease, and Antibody Response to COVID-19 in Patients With Inflammatory Rheumatic Diseases in Portugal—A Multicenter, Nationwide Study
Ana Rita Cruz-Machado,Sofia C. Barreira,Matilde Bandeira,Marc Veldhoen,Andreia Gomes,Marta Serrano,Catarina Duarte,Maria Rato,Bruno Miguel Fernandes,Salomé Garcia,Filipe Pinheiro,Miguel Bernardes,Nathalie Madeira,Cláudia Miguel,Rita Torres,Ana Bento Silva,Jorge Pestana,Diogo Almeida,Carolina Mazeda,Filipe Cunha Santos,Patrícia Pinto,Marlene Sousa,Hugo Parente,Graça Sequeira,Maria José Santos,João Eurico Fonseca,Vasco C. Romão
DOI: https://doi.org/10.3389/fmed.2022.901817
IF: 3.9
2022-06-13
Frontiers in Medicine
Abstract:Objective To identify risk factors for SARS-CoV-2 infection and for severe/critical COVID-19, and to assess the humoral response after COVID-19 in these patients. Methods Nationwide study of adult patients with inflammatory RMDs prospectively followed in the Rheumatic Diseases Portuguese Register—Reuma.pt—during the first 6 months of the pandemic. We compared patients with COVID-19 with those who did not develop the disease and patients with mild/moderate disease with those exhibiting severe/critical COVID-19. IgG antibodies against SARS-CoV-2 were measured ≥3 months after infection and results were compared with matched controls. Results 162 cases of COVID-19 were registered in a total of 6,363 appointments. Patients treated with TNF inhibitors (TNFi; OR = 0.160, 95% CI 0.099–0.260, P < 0.001) and tocilizumab (OR 0.147, 95% CI 0.053–0.408, P < 0.001) had reduced odds of infection. Further, TNFi tended to be protective of severe and critical disease. Older age, major comorbidities, and rituximab were associated with an increased risk of infection and worse prognosis. Most patients with inflammatory RMDs (86.2%) developed a robust antibody response. Seroconversion was associated with symptomatic disease (OR 13.46, 95% CI 2.21–81.85, P = 0.005) and tended to be blunted by TNFi (OR 0.17, 95% CI 0.03–1.05; P = 0.057). Conclusions TNFi and tocilizumab reduced the risk of infection by SARS-CoV-2. Treatment with TNFi also tended to reduce rates of severe disease and seroconversion. Older age, general comorbidities and rituximab were associated with increased risk for infection and worse prognosis, in line with previous reports. Most patients with RMDs developed a proper antibody response after COVID-19, particularly if they had symptomatic disease.
medicine, general & internal